Your browser doesn't support javascript.
loading
Novel AIP mutation in exon 6 causing acromegaly in a German family.
Detomas, M; Altieri, B; Flitsch, J; Saeger, W; Korbonits, M; Deutschbein, T.
Affiliation
  • Detomas M; Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, Würzburg, Germany. detomas_m@ukw.de.
  • Altieri B; Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, Würzburg, Germany.
  • Flitsch J; Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Saeger W; Institute of Neuropathology, University of Hamburg, UKE, Hamburg, Germany.
  • Korbonits M; Centre for Endocrinology, Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, UK.
  • Deutschbein T; Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, Würzburg, Germany.
J Endocrinol Invest ; 46(8): 1705-1709, 2023 Aug.
Article in En | MEDLINE | ID: mdl-36757586
The most frequent genetic alteration of familial isolated growth hormone producing pituitary neuroendocrine tumors is a germline mutation of the aryl hydrocarbon receptor-interacting protein (AIP) gene. Various AIP mutations are already known; however, an AIP mutation in exon 6 (c.811_812del; p.Arg271Glyfs*16) has not been reported yet. Here, we report a German family with two identical twins who were both affected by acromegaly and carried the above-mentioned novel AIP mutation. The father was found to be an unaffected carrier, while the paternal aunt most likely suffered from acromegaly as well and died from metastatic colorectal cancer. Apart from reporting a novel AIP mutation, this study does not only highlight the different clinical and histological features of the AIP mutated growth hormone producing pituitary neuroendocrine tumors but also confirms the poor responsiveness of dopamine agonists in AIP mutated acromegaly. Furthermore, it highlights the increased mortality risk of comorbidities typically associated with acromegaly.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pituitary Neoplasms / Acromegaly / Adenoma / Neuroendocrine Tumors / Growth Hormone-Secreting Pituitary Adenoma Limits: Humans Language: En Journal: J Endocrinol Invest Year: 2023 Document type: Article Affiliation country: Germany Country of publication: Italy

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pituitary Neoplasms / Acromegaly / Adenoma / Neuroendocrine Tumors / Growth Hormone-Secreting Pituitary Adenoma Limits: Humans Language: En Journal: J Endocrinol Invest Year: 2023 Document type: Article Affiliation country: Germany Country of publication: Italy